N-Palmitoylethanolamide enhances antinociceptive effect of tramadol in neuropathic rats
Laboratory studyOther animalsWith tramadol
This study tested palmitoylethanolamide together with tramadol. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- 126 male Wistar rats with chronic constriction injury neuropathic pain, in 21 groups
- Dose used in the study
- Oral tramadol (1.0 to 31.62 mg/kg), PEA (0.0316 to 10 mg/kg), or combinations (tramadol 1.0 to 10 mg/kg with PEA 0.0316 to 1.0 mg/kg); gabapentin (1.0 to 177.78 mg/kg) as a comparator
- Duration
- Not stated in the abstract
- What was measured
- Anti-hyperalgesic and anti-allodynic effects by dose-response analysis; motor coordination; constipation; surface of synergistic interaction analysis.
What the authors reported
PEA alone was about five times more potent than tramadol against hyperalgesia and about eight times more potent against allodynia. The combination of tramadol 10 mg/kg plus PEA 0.0316 mg/kg gave the strongest anti-hyperalgesic and anti-allodynic effects among combinations tested, with no added effect on motor coordination or constipation compared with vehicle.
Limits of this study
A rat model of chronic constriction injury pain; it cannot show effect in people. The authors declare no competing financial interests.
Source
PubMed 39721328 · doi:10.1016/j.biopha.2024.117760
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.